Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:KNSA NASDAQ:RARE NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$9.70+6.2%$9.78$5.03▼$14.44$832.19M0.831.11 million shs435,342 shsKNSAKiniksa Pharmaceuticals International$37.81+0.9%$34.24$17.82▼$39.12$2.81B0.16643,863 shs38,809 shsRAREUltragenyx Pharmaceutical$31.31+1.3%$29.36$25.81▼$57.99$3.02B0.211.34 million shs138,697 shsVKTXViking Therapeutics$28.30+1.5%$29.39$18.92▼$81.73$3.18B0.644.81 million shs1.15 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+1.33%+7.41%-3.69%-14.83%+61.45%KNSAKiniksa Pharmaceuticals International-3.03%+5.52%+9.31%+34.52%+52.75%RAREUltragenyx Pharmaceutical+3.03%+11.07%-3.53%-21.15%-44.37%VKTXViking Therapeutics+1.86%+11.12%+1.42%-0.99%-56.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$9.70+6.2%$9.78$5.03▼$14.44$832.19M0.831.11 million shs435,342 shsKNSAKiniksa Pharmaceuticals International$37.81+0.9%$34.24$17.82▼$39.12$2.81B0.16643,863 shs38,809 shsRAREUltragenyx Pharmaceutical$31.31+1.3%$29.36$25.81▼$57.99$3.02B0.211.34 million shs138,697 shsVKTXViking Therapeutics$28.30+1.5%$29.39$18.92▼$81.73$3.18B0.644.81 million shs1.15 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+1.33%+7.41%-3.69%-14.83%+61.45%KNSAKiniksa Pharmaceuticals International-3.03%+5.52%+9.31%+34.52%+52.75%RAREUltragenyx Pharmaceutical+3.03%+11.07%-3.53%-21.15%-44.37%VKTXViking Therapeutics+1.86%+11.12%+1.42%-0.99%-56.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.00Buy$44.00353.84% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$44.2917.12% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50160.28% UpsideVKTXViking Therapeutics 3.00Buy$86.42205.38% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, RARE, VKTX, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/1/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.009/29/2025KNSAKiniksa Pharmaceuticals InternationalTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/29/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.009/25/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $45.009/22/2025VKTXViking TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.009/10/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/10/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.008/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.00(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AKNSAKiniksa Pharmaceuticals International$423.24M6.62N/AN/A$6.60 per share5.73RAREUltragenyx Pharmaceutical$560.23M5.39N/AN/A$2.76 per share11.34VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%11/28/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04946.49151.25N/A0.90%1.05%0.80%11/4/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest AVXL, RARE, VKTX, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/22/2025Q3 2025VKTXViking Therapeutics-$0.71N/AN/AN/AN/AN/A8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 million7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A8.938.93KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16RAREUltragenyx PharmaceuticalN/A2.452.30VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%KNSAKiniksa Pharmaceuticals International53.95%RAREUltragenyx Pharmaceutical97.67%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%KNSAKiniksa Pharmaceuticals International53.48%RAREUltragenyx Pharmaceutical5.50%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableAVXL, RARE, VKTX, and KNSA HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to KnowOctober 2 at 6:45 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Up 1.9% - Should You Buy?October 2 at 5:42 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 4.1% - Should You Buy?October 1 at 6:58 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating from HC WainwrightOctober 1 at 2:37 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Up 1.8% - Here's WhySeptember 30 at 6:57 PM | marketbeat.comBTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PTSeptember 30 at 3:11 PM | insidermonkey.comBTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX)September 30 at 5:13 AM | msn.comViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at HC WainwrightSeptember 29, 2025 | marketbeat.comViking Therapeutics: Overdue For GainsSeptember 28, 2025 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for InvestorsSeptember 25, 2025 | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Down 5.8% - Here's WhySeptember 25, 2025 | marketbeat.comBrokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetSeptember 25, 2025 | zacks.comCan Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?September 25, 2025 | zacks.comViking Therapeutics (NASDAQ:VKTX) Trading 6.6% Higher - Time to Buy?September 24, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading 7.4% Higher - What's Next?September 24, 2025 | marketbeat.comU.S. Capital Wealth Advisors LLC Purchases 27,795 Shares of Viking Therapeutics, Inc. $VKTXSeptember 24, 2025 | marketbeat.comBTIG Research Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)September 24, 2025 | americanbankingnews.comPfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX)September 23, 2025 | msn.comViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowSeptember 23, 2025 | zacks.comViking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeptember 23, 2025 | seekingalpha.comExchange Traded Concepts LLC Buys 20,296 Shares of Viking Therapeutics, Inc. $VKTXSeptember 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025Lithium Americas Rally Lifts Other Rare Earth Stocks By Gabriel Osorio-Mazilli | September 25, 2025AVXL, RARE, VKTX, and KNSA Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$9.70 +0.57 (+6.19%) As of 11:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Kiniksa Pharmaceuticals International NASDAQ:KNSA$37.81 +0.34 (+0.92%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Ultragenyx Pharmaceutical NASDAQ:RARE$31.31 +0.41 (+1.33%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Viking Therapeutics NASDAQ:VKTX$28.30 +0.42 (+1.50%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play General Dynamics Hits New Highs: Why It Might Keep Climbing Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
